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Background: All of the components of Metabolic syndrome (MetS) have been regarded as risk factors for coronary
artery disease (CAD). Early detection of CAD in asymptomatic patients with MetS remains a challenge. Cystatin C,
which has been proposed as a novel marker of renal dysfunction,is correlated with mortality in CAD, The purpose
of the study was to evaluate whether cystatin C is a potential marker of asymptomatic CAD in MetS patients with
normal kidney function.
Methods: A total of 211asymptomatic MetS patients without prior history of CAD patients were included in a
cross-sectional study. Patients were divided into MetS with asymptomatic CAD (n = 136) and MetS without CAD
(n = 75) groups according to coronary angiograph results. Serum cystatin C levels were measured using particle
enhanced immunonephelometric assays. We first assessed whether there is an independent association of cystatin
C with the presence and severity of asymptomatic CAD. Then, we investigated the association between cystatin C
and other biochemical risk factors for atherosclerosis.
Results: Serum cystatin C levels in patients with asymptomatic CAD were significantly higher than those without
CAD (P = 0.004). A multiple logistic regression analysis demonstrated cystatin C was independently associated with
the presence of asymptomatic CAD (OR = 1.326, 95%CI: 1.086-1.619). On receiver operating characteristics (ROC)
analysis, the area under the curve (AUC) was 0.622 (95 % CI: 0543–0.701, P= 0.003), and cystatin C showed a
moderate predictive value. Furthermore, cystatin C was independently correlated with Gensini score (standardized
β= 0.183, P= 0.007), and serum cystatin C levels increased with the increasing of number of disease vessels
(P = 0.005). In a multiple stepwise regression analysis, uric acid (UA)(P< 0.001), body mass index (BMI)(P = 0.002),
triglyceride(TG)(P= 0.03), estimated glomerular filtration rate (eGFR)(P< 0.001), and fibrinogen(P= 0.001) were
independently associated with cystatin C.
Conclusions: Serum cystatin C in our study was significantly associated with the presence and severity of
asymptomatic CAD in MetS patients with normal kidney function, suggesting that cystatin C is probably more than
a marker of glomerular filtration rate.
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Metabolic syndrome (MetS) is a clinical entity character-
ized by abdominal obesity, hyperglycaemia, hypertension,
and dyslipidaemia. Until now, the pathophysiology of
MetS is not well defined [1]. Each of the components have
been recognized as risk factors for coronary artery disease* Correspondence: gaoling1@medmail.com.cn
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reproduction in any medium, provided the or(CAD)[2], and today a series of previous studies have
demonstrated that the presence of MetS is associated with
an increased risk of developing CAD [3,4]. CAD is the
leading cause of morbidity and mortality worldwide.
Asymptomatic patients have a higher cardiac mortality
risk than those with symptomatic CAD [5]. An early iden-
tification and treatment of asymptomatic CAD patients
may significantly improve their cardiovascular prognosis.
Unfortunately, the early diagnosis of asymptomatic CADd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of cardiac ischemia are often masked. To date, classic as-
sessment such as Framingham Risk Score (FRS) could not
identify asymptomatic CAD effectively. Biochemical mar-
kers might play crucial roles on initial assessment of
asymptomatic CAD.
Cystatin C belongs to a family of competitive inhibi-
tors of lysosomal cysteine protease and is synthesized at
a constant rate in all nucleated cells [6]. Compared with
serum creatinine, cystatin C is less influenced by age,
sex, and race, and a combined creatinine-cystatin C
equation performed better than equations that used cre-
atinine alone for classification of the estimating glom-
erular filtration rate (eGFR) [7]. Cystatin C has emerged
as a novel sensitive marker for detecting renal dysfunc-
tion [8,9]. Recent studies have revealed that cystatin C is
not simply regarded as a candidate marker of impaired
kidney function. In Prospective Epidemiological Study of
Myocardial Infarction (PRIME), cystatin C predicted the
occurrence of the first coronary events in men aged 50
to 59 years old, and displayed a strong relation with
CAD independent of eGFR [10]. Several other publica-
tions have demonstrated that cystatin C was closely
associated with incident congestive heart failure [11], ca-
rotid atherosclerosis [12] and peripheral vascular disease
[13] superior to serum creatinine or creatinine-based
eGFR.
In addition to the association with atherosclerosis,
connections between cystatin C and features of the MetS
have also been illustrated by a few recently published
studies [14,15]. In a cross-sectional study included 925
dyslipidaemic patients, Aude Servais et al. [16] found
that a progressive increase in serum cystatin C occurred
in parallel with an increase in the number of MetS com-
ponents. To date, the link between cystatin C and
asymptomatic CAD in MetS patients remains to be elu-
cidated. The current study was designed to investigate
whether there is an independent association of cystatin
C with the presence and severity of asymptomatic CAD
in MetS patients with normal kidney function and to ex-
plore the relationship between cystatin C and other bio-
chemical risk factors for atherosclerosis.
Methods
Study subjects
This was a cross-sectional study consisted of 211
asymptomatic MetS patients without prior diagnosed
CAD and with normal eGFR who presented for a an-
nual medical evaluation at QiLu Hospital of Shandong
University (Jinan, China)from March 2010 to March
2012. All patients had abnormal ECG findings include
the ST segment abnormalities, T wave abnormalities,
and other abnormalities indicate myocardium ischemia
and referred to a coronary artery angiography forsuspected asymptomatic CAD. The patients were
divided into MetS with asymptomatic CAD (n = 136)
and MetS without asymptomatic CAD (n = 75) groups
according to their coronary angiography results. Indivi-
duals with angina pectoris or anginal-equivalent symp-
toms suggestive of CAD, valvular heart disease,
malignancy, inflammatory disease, renal dysfunction
(creatinine-based eGFR <90 mL/min/1.73 m2 calculated
by Cockcroft-Gault formula, serum creatinine > 133
umol/L), hepatic dysfunction were excluded from the
study. Studies have shown that large doses of glucocor-
ticoids would increase the production of cystatin C
[17]. Thyroid dysfunction also has a major impact on
cystatin C levels. Serum levels of cystatin C are lower
in the hypothyroid state and higher in the hyperthy-
roid state [18,19]. Patients with above factors were also
excluded from this study to eliminate potential con-
founding factors. The study protocol complied with
the Declaration of Helsinki and was approved by the
Clinical Research Ethics Committee of QiLu Hospital,
Medical College of Shandong University. Written
informed consent was obtained from all subjects.
Diagnostic criteria
(1)The diagnostic criteria for MetS were based on the
revised Adult Treatment Panel III criteria (revised ATP-
III) [20]. Because waist circumference was not available
in this study, BMI was employed as a surrogate for waist
circumference as has been used to define MetS by the
Chinese Diabetes Society [21]. Patients met with at least
three or more of the following conditions were diag-
nosed with MetS :
Reduced high-density lipoprotein cholesterol (HDL-C):
①HDL-C <1.03 mmol/L (male) or < 1.29 mmol/L (fe-
male); ②Hyperglycaemia: fasting plasma glucose
(FPG)≥ 5.6 mmol/L or antidiabetic medication use;
③Hypertension: systolic blood pressure or diastolic
blood pressure(SBP/DBP) ≥ 130/85 mmHg and/or diag-
nosed hypertension treated with antihypertensive ther-
apy; ④Elevated triglycerides (TG): TG ≥ 1.7 mmol/L or
receiving specific treatment for this lipid abnormality;
⑤Body mass index (BMI) ≥25 kg/m2.
(2)Asymptomatic CAD patients were diagnosed
according to the Monica criteria [22]: two or more ECG
showing specific changes without suggestive symptoms,
and confirmed by the presence of at least one lesion
with ≥50% luminal stenosis by coronary angiography.
Abnormal ECG findings include the ST segment abnor-
malities, T wave abnormalities, and other abnormalities
indicate myocardium ischemia.
Clinical and biochemical assessment
Demographic characteristics and cardiovascular risk factors
were obtained from medical records. The cardiovascular
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≥140/90 mmHg or taking anti-hypertensive drugs), smok-
ing status (≥20 packs per year), and diabetes mellitus (fast-
ing plasma glucose level≥ 6.1 mmol/L or taking insulin or
oral hypoglycaemic drugs). Hypercholesterolemia (total
cholesterol level ≥5.0 mmol/L or use of lipid-lowering
medication). BMI was calculated as weight (kg) divided by
the square of the height (m2). Systolic and diastolic blood
pressures were measured using standard methods.
Venous blood was collected after overnight fasting be-
fore coronary artery angiography. Serum was stored at
−80°C and was used to analyse of total cholesterol (TC),
low-density lipoprotein cholesterol (LDL-c), high-density
lipoprotein cholesterol(HDL-c), triglycerides (TG), uric
acid(UA) and fasting plasma glucose(FPG) using an
automatic biochemistry analyzer (Roche Cobas 8000
modular analyzer Series C701, Mannheim, Germany).
Concentrations of serum cystatin C were determined
using Roche Cobas 8000 modular analyzer Series
(Roche, Inc., Mannheim, Germany) with a particle-
enhanced immunonephelometric assay (Roche Tina-
quant Cystatin C, Roche, Inc., Mannheim, Germany).
The laboratory reference ranges for cystatin C was 0.4 to
8.0 mg/L, and the intra-assay and inter-assay coefficients
of variation were 0.9 % and 2.9 %, respectively. Fibrinogen
was measured using Von Clauss methods on an electro-
mechanical coagulometers (STA-R, Diagnostica Stago,
Asnieres, France). Serum creatinine(sCr) levels were mea-
sured using an enzymatic method, and eGFR was esti-
mated with the Cockcroft-Gault formula [23]. Participants
with an eGFR<90 mL/min/1.73 m2 were excluded.
Coronary angiography
Coronary artery angiography was performed using
standard Judkins techniques. Angiographic analysis was
conducted by two expert investigators who were blinded
to the study protocol. The extent of CAD was described
as 0-, 1-, 2-, or 3-vessel disease based on the number of
coronary vessels with >50% luminal narrowing. The se-
verity of coronary atherosclerosis was scored based on
Gensini scoring [24].
Statistical analysis
Continuous variables with normal distribution were
expressed as the mean± SD, while percentages were
used to express categorical variables. Variables such as
TG, HDL-C, Gensini score that were not normally dis-
tributed, as determined by the Kolmogorov–Smirnov
test, were logarithmically transformed before analysis
and expressed as medians with inter quartile range. The
chi-square test was used to compare the categorical vari-
ables of subjects with and without CAD. An unpaired
student’s t test was used for normally distributed vari-
ables and the Mann–Whitney U-test was used forskewed variables. Pearson and partial correlation analysis
were applied to determine factors that correlated with
cystatin C, and Spearman correlation analysis was per-
formed to determine factors that correlated with Gensini
score. To determine the independent parameters corre-
lated with cystatin C and the Gensini score, the para-
meters that correlated significantly in the univariate
analysis and other parameters that were biologically rele-
vant to cystatin C and the Gensini score were tested
using multiple stepwise regression analysis. A logistic re-
gression analysis was performed to assess the association
between the presence of CAD and cystatin C levels. Age,
gender, BMI, smoking state, hypertension, diabetes, lipid
profile(TC,TG LDL-c, HDL-c), and eGFR were consid-
ered to be potential confounders and were adjusted in
the different models. In addition, the receiver operating
characteristics (ROC) curve was used to determine the
cystatin C cut-off for predicting asymptomatic CAD. All
statistical analyses were performed using SPSS 16.0 soft-
ware for Windows (SPSS, Chicago, IL, USA). A two-
tailed P-value < 0.05 was set as the level of significance.
Results
Characteristics of the study subjects
The characteristics of the study subjects are described in
Table 1. The patients with asymptomatic CAD were
older than those without CAD(P= 0.011).The rates of
hypertension and diabetes mellitus in patients with
asymptomatic CAD were higher than in patients without
CAD, and asymptomatic CAD patients showed an in-
crease of FPG (P= 0.011). The fibrinogen concentrations
were significantly higher in patients with asymptomatic
CAD than in those without CAD (P= 0.012). However,
there was no difference in sCr, eGFR and lipid profiles
between patients with asymptomatic CAD and without
CAD. Among the patients with MetS, those with asymp-
tomatic CAD had significantly higher serum cystatin C
levels than those without CAD (0.93 ± 0.18 vs
0.86 ± 0.16 mg/L, P= 0.004; Figure 1A).
Relationship between serum cystatin C and the presence
of asymptomatic CAD
Multiple logistic regression analysis was performed using
the presence of the asymptomatic CAD as a dependent
variable (Table 2). The analysis involved age, sex, BMI,
smoking, hypertension, diabetes and biochemical risk
factors, including TC LDL-c, HDL-c, TG, SBP, DBP, fi-
brinogen, FPG, eGFR and cystatin C. As a result, serum
cystatin C (odds ratio, OR= 1.326, 95% confidence inter-
val(CI):1.086-1.619, P= 0.006), fibrinogen (OR= 1.629,
95% CI: 1.043-2.543, P= 0.032), FPG (OR= 1.363, 95%
CI: 1.088-1.707, P= 0.007) and smoking (OR= 1.913,
95% CI: 1.007-3.633, P= 0.048) were independent predic-
tors of the presence of the asymptomatic CAD.
Table 1 Clinical and biochemical characteristics of the
study subjects
Non-CAD(n = 75) CAD(n= 136) P
Age(years) 55.05 ± 9.47 58.82 ± 10.54 0.011
Males% (n) 57(43) 65(88) 0.291
Current smokers%(n) 31(23) 46(74) 0.027
Hypertension%(n) 68(51) 78(106) 0.113
Diabetes%(n) 33(25) 37(50) 0.618
BMI(kg/m2) 27.43 ± 2.20 27.24 ± 2.57 0.580
Systolic BP(mmHg) 141.11± 17.05 141.79 ± 19.05 0.801
Diastolic BP(mmHg) 82.08 ± 13.33 81.161 ± 14.29 0.648
HR(bpm) 74.67 ± 12.66 72.82 ± 11.69 0.289
FPG(mmol/L) 5.97 ± 1.34 6.53 ± 1.58 0.011
TC(mmol/L) 4.86 ± 1.12 5.02 ± 1.14 0.341
TG(mmol/L) 1.92(1.58-2.18) 2.09(1.48-2.57) 0.197
LDL-c(mmol/L) 2.82 ± 0.85 2.89 ± 0.93 0.549
HDL-c(mmol/L) 1.06(0.93-1.23) 1.06(0.91-1.21) 0.541
SCr(mmol/L) 70.73 ± 16.74 70.56 ± 13.59 0.938
CG-eGFR(ml/min/1.73 m2) 112.04± 27.60 104.92 ± 26.04 0.064
UA(μmol/L) 319.00± 82.47 331.56 ± 94.53 0.335
Fibrinogen(g/L) 3.30 ± 0.68 3.58 ± 0.78 0.012
Cystatin C(mg/L) 0.86 ± 0.16 0.93 ± 0.18 0.004
Gensini score 8.00(2.5-12.00) 42.0(27–53.75) <0.001
BMI, body mass index; BP, blood pressure; HR, heart rate; FPG, fasting plasma
glucose; TC, total cholesterol; TG, triglyceride; LDL-c, low-density lipoprotein
cholesterol; HDL-c, high-density lipoprotein cholesterol; SCr, serum creatinine;
UA, uric acid. Data are means ± SD or median (interquartile range).
Qing et al. Cardiovascular Diabetology 2012, 11:108 Page 4 of 9
http://www.cardiab.com/content/11/1/108The ability of serum cystatin C levels to distinguish
MetS patients with asymptomatic CAD from those with-
out CAD was assessed using ROC curve analysis. The
ROC curves for asymptomatic CAD diagnosis had an
area under the curve (AUC) of 0.622 (95% CI: 0543–
0.701, P= 0.003). A serum cystatin C level of ≥0.825 mg/
L predicted the presence of CAD with a sensitivity of
71.3% and specificity of 54.7% (Figure 2).
Correlation between serum cystatin C and the clinical
biochemical parameters
We next investigated the relationship between serum
cystatin C levels and clinical biochemical parameters.
The Pearson correlation analysis demonstrated that
serum cystatin C was positively correlated with age, UA,
sCr, and fibrinogen and negatively correlated with eGFR
(P < 0.01). After further adjustment for age, sex and
eGFR, the positive correlation remained significant be-
tween cystatin C and UA, fibrinogen (P < 0.001,
P= 0.001, respectively). A positive correlation was also
observed between cystatin C and TG and BMI
(P= 0.031, P < 0.001, respectively, Table 3). Furthermore,
multivariate stepwise regression analysis was performedto evaluate the independent factors of cystatin C with
age and the factors identified in the above univariate
analysis including UA, BMI, TG, eGFR, and fibrinogen
as independent variables. The analysis demonstrated that
UA (standardized β= 0.233, P < 0.001), BMI (standar-
dized β= 0.176, P= 0.002), TG (standardized β= 0.117,
P= 0.03), eGFR (standardized β=−0.455, P < 0.001), and
fibrinogen (standardized β= 0.187, P= 0.001) were inde-
pendently associated with serum cystatin C.
Correlation between serum cystatin C and CAD severity
Spearman correlation analysis showed that serum cysta-
tin C (r = 0.188, P= 0.006; Figure 3) was positively corre-
lated with the Gensini score. We further performed a
multivariate stepwise regression analysis to evaluate the
association between serum cystatin C levels and the
Gensini score in a model including age, sex, BMI, smok-
ing, hypertension, and diabetes as well as TC LDL-c,
HDL-c, TG SBP, DBP, fibrinogen, FPG, eGFR and cysta-
tin C. The adjustment for the covariates did not change
the associations significantly. Serum cystatin C was the
independent factor that significantly influenced the Gen-
sini score (standardized β= 0.183, P= 0.007, 95%CI:
0.602-3.844, Table 4).
All of the subjects were further divided into four
groups according to the number of disease vessels
(N= 0, 1, 2, 3). The serum cystatin C levels were
0.86 ± 0.17, 0.90 ± 0.16, 0.92 ± 0.17 and 0.97 ± 0.19 mg/L
in the groups with disease vessels of 0, 1, 2, and 3, re-
spectively, and the serum levels of cystatin C increased
as the number of stenotic vessels increased (P= 0.005).
The cystatin C level in the group N= 0 was significantly
lower than those in the groups of N= 2 and N=3
(P= 0.042 and P ≤ 0.001, respectively, Figure 1B). No sig-
nificance was found for cystatin C levels in the N= 0
and N=1 groups. Moreover, the serum cystatin C levels
were significantly higher in the N=3 group than in the
N=1 group (P= 0.045).
Discussion
In the present study, we demonstrated that in asymp-
tomatic MetS patients without prior diagnosed CAD
and with normal creatinine-based eGFR, elevated serum
cystatin C was independently associated with the pres-
ence of asymptomatic CAD, even in an adjusted model.
Serum cystatin C levels were positively and significantly
correlated with the Gensini score. Furthermore, a posi-
tive association was also illustrated between serum
cystatin C concentrations and the number of coronary
arteries with luminal stenosis vessels. To the best of our
knowledge, the study is the first to identify cystatin C as
an independent risk factor for the development and se-
verity of asymptomatic CAD in subjects with MetS and
normal creatinine-based eGFR.
Figure 1 Serum cystatin C levels between MetS patients with asymptomatic CAD (n= 136) and those without CAD (n = 75) (A). CAD,
coronary artery disease; MetS, metabolic syndrome. Comparison of serum cystatin C levels according to the number of stenotic coronary arteries
(n = 75, 40, 56, 40, respectively, in 0, 1, 2and 3 stenotic vessels group)(B).
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function are at significantly higher risk for cardiovascu-
lar disease, congestive heart failure, all-cause mortality
and adverse long-term outcomes in contrast to patients
without renal disease [25-27]. Cystatin C has been
regarded as a novel sensitive marker for the assessment
of renal function, and the role of cystatin C as a pre-
dictor of cardiovascular events in patients with impaired
renal function has been confirmed in clinical studies. Inthis study we assessed the association between cystatin
C and asymptomatic CAD in a consecutive series of
MetS patients with normal kidney function in order to
avoid the well-known effect of overt renal insufficiency
on coronary atherosclerosis, and evaluate whether cysta-
tin C has an ability to identify individuals at a higher risk
for CAD among patients belonging to a low-risk cat-
egory according to eGFR. The current study demon-
strated that serum levels of cystatin C, but not sCr and
Table 2 Multiple stepwise logistic regression analysis
indicating factors independently associated with
asymptomatic CAD
Parameters Exp(B) 95% CI P
Fibrinogen 1.629 1.043-2.543 0.032
FPG 1.363 1.088-1.707 0.007
Smoking 1.913 1.007-3.633 0.048
Cystatin C 1.326 1.086-1.619 0.006
CAD, coronary artery disease; CI, confidence interval; FPG, fasting plasma
glucose.
Variables included in the model are age, sex, BMI, smoking, hypertension,
diabetes and biochemical risk factors TC, LDL-c, HDL-c, TG, SBP, DBP,
fibrinogen, FPG, eGFR and cystatin C.
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ment of asymptomatic CAD, even after a variety of po-
tential confounders were controlled. In accordance with
our study, Wang et al. demonstrated elevated cystatin C
was associated with the presence of CAD in subjects
with mild renal impairment, while creatinine and eGFR
were not able to predict CAD occurrence [28]. Similar
findings were also observed by Koenig and his colleagues
[29], who reported that cystatin C was superior to cre-
atinine or eGFR for predicting cardiovascular events in a
cohort of 1033 patients with CAD. Recently, the close
relationship between cystatin C and all-cause cardiovas-
cular mortality has been illustrated in subjects with nor-
mal eGFR [30], which further confirmed that cystatin C
may not simply be regarded as an indicator of the asso-
ciation between renal dysfunction and an increased riskFigure 2 ROC curve analyses for predictive values of serum
cystatin C levels in detecting asymptomatic CAD;ROC, receiver
operating characteristic; CAD, coronary artery disease.of CAD, the information contained by cystatin C repre-
sents more than just a marker of renal function.
Although cystatin C was independently associated with
the presence of asymptomatic CAD,in the ROC analysis,
the AUC for cystatin C falls into the range 0.6–0.7,
which indicates the predictive value of cystatin as a sole
marker was only moderate, and the cut-off value of
0.825 mg/L can not be categorized as ideal value to
identify asymptomatic CAD effectively. Nevertheless, the
addition of cystatin C may compensate for the inad-
equacy of. other classical parameters such as FRS for
asymptomatic CAD. Future studies should investigate
the feasibility of combined use of cystatin C and other
parameters to improve the predictive value the presence
of asymptomatic CAD.
In addition, when the associations between cystatin C
and severity of asymptomatic CAD were evaluated, we
found a positive relationship between serum levels of
cystatin C and the number of diseased vessels. A positive
association was also found between serum cystatin C
levels and the Gensini score independent of eGFR, even
after adjustment for established risk factors associated
with cardiovascular disease and cystatin C. Similar
results were also reported by Niccoli et al. [31], who
demonstrated that the independent association between
cystatin C and CAD severity was superior to that of cre-
atinine or eGFR. In contrast, Kim et al. [32] failed to
demonstrate an association between serum cystatin C
and CAD in a retrospective study which included 64 dia-
betic patients, although they found an association be-
tween cystatin C and renal dysfunction. The small
sample size might explain these discrepancies.
Detailed mechanisms underlying link between cystatin
C and asymptomatic CAD have not been fully eluci-
dated. Renal mechanism seems to be a plausible link be-
tween increased cystatin C and asymptomatic CAD.
Serum cystatin C was assumed to be a sensitive indicator
of“pre-clinical” renal disease which can not be detected
by eGFR based on serum creatinine [33]. Cystatin C may
thus help to identify individuals who are at increased
risk for the development of asymptomatic CAD among
patients with MetS and normal creatinine-based eGFR.
Besides renal mechanism, another possible explanation
for the close relationship between cystatin C and.
asymptomatic CAD is that cystatin C is associated with
inflammation regardless of renal function Inflammation
is a critical step in the development of atherosclerosis.
Inflammatory cytokines associated with atherosclerosis
may alter the relationship between cysteine protease and
their endogenous inhibitors like cystatin C. The imbal-
ance of cysteine protease and its inhibitor may increase
the degradation of extracellular matrix and migration of
monocytes, macrophages and vascular smooth muscle
cells into the intima, thus leading to the development of
Table 3 Correlation of serum cystatin C levels with clinical and biological parameters
Variables Cystatin C Cystatin C (adjust for age sex and eGFR)
r P r P
Age(years) 0.267 <0.001 _ _
BMI(kg/m2) 0.062 0.379 0.299 <0.001
HR(bpm) −0.091 0.193 0.002 0.981
Systolic BP(mmHg) 0.003 0.961 0.036 0.609
Diastolic BP(mmHg) 0.009 0.895 0.069 0.331
TC(mmol/L) 0.105 0.135 0.122 0.083
TG(mmol/L)* 0.048 0.495 0.152 0.031
LDL-c(mmol/L) −0.004 0.956 0.006 0.930
HDL-c(mmol/L)* 0.007 0.925 −0.026 0.713
Fibrinogen(g/L) 0.173 0.013 0.242 0.001
FPG(mmol/L) −0.053 0.455 −0.102 0.149
UA(μmol/L) 0.382 <0.001 0.370 <0.001
SCr(mmol/L) 0.464 <0.001 _ _
eGFR(ml/min/1.73 m2) −0.473 <0.001 _ _
BMI, body mass index; HR, heart rate; BP, blood pressure; TC, total cholesterol; TG, triglyceride; LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density
lipoprotein cholesterol; FPG, fasting plasma glucose; UA, uric acid; SCr, serum creatinine.
*Log transformed before analysis.
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from 990 patients with CAD indicated significant asso-
ciations between cystatin C and proinflammatory para-
meters like C-reactive protein (CRP) or fibrinogen [36].
Similar results were shown in the Cardiovascular Health
Study, which demonstrated cystatin C was correlated
with CRP and fibrinogen in patients with mild to moder-
ate renal dysfunction [37]. Consistent with these studies,Figure 3 Correlation between serum cystatin C and the severity of as
disease.we found a significant correlation between cystatin C
and fibrinogen, whereas the correlations between fi-
brinogen and other renal markers such as serum Cr and
eGFR were weak and insignificant. This may at least
partly explain the complicated underlying link between
cystatin C and asymptomatic CAD.
Uric acid has been shown to be related with increased
production of oxygen free radicals, to promote theymptomatic CAD evaluated by Gensini score. CAD, coronary artery
Table 4 Multiple stepwise regression analysis showing
variables independently associated with Gensini score
Variables Beta Coefficients P 95% CI
Cystatin C 0.183 0.007 0.602-3.844
FPG 0.195 0.004 0.867-4.483
Fibrinogen 0.184 0.007 1.418-8.856
FPG, fasting plasma glucose, CI, confidence interval.
Variables included in the model are age, sex, BMI, smoking, hypertension, and
diabetes and biochemical risk factors TC LDL-c, HDL-c, TG SBP, DBP,
fibrinogen, FPG, eGFR and cystatin C.
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[38]. Studies have shown increased uric acid levels are
associated with atherosclerosis [39]. Apart from the
strong correlation with creatinine and eGFR as expected,
our data from MetS patients demonstrated that cystatin
C was significantly positively correlated with uric acid.
These findings are in accordance with previous reports
about cystatin C and uric acid in patients with type 2
diabetes [40] and in a hypertensive population [41].
There were some limitations in our study which should
be considered. First, we did not collect 24-hour urine for
direct measurements of GFR because of its difficulty in
daily practice. Instead, we assessed renal function with
the commonly used Cockcroft-Gault formula which has
some minor flaws that may lead to substantial bias in the
assessment. However, numerous studies have demon-
strated that the creatinine-based eGFR provides a good
approximation. Second, to avoid confounding, we
adjusted for well-known confounders such as gender,
age, smoking status, and BMI. However, residual con-
founding may have occurred. Third, our results are
derived from a cross-sectional study. Further studies, es-
pecially larger, population-based prospective studies are
required to validate the findings suggested by the current
study.Conclusions
In conclusion, our findings demonstrate that cystatin C
was significantly associated with the presence and sever-
ity of asymptomatic CAD in MetS patients with normal
kidney function. Probably cystatin C is more than a mar-
ker of glomerular filtration rate. Further research is war-
ranted to clarify the pathophysiologic mechanisms
responsible for this association.
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